Peter C O'Brien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter C O'Brien has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- James William Denham
School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
2 shared publications C Hamilton
Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales, Australia
1 shared publicationC.Ian V Franklin
1 shared publication- Chris Wratten
Radiation Oncology Department, Calvary Mater Newcastle, Newcastle, Australia
1 shared publication Christopher S Hamilton
1 shared publicationDaniel E. Roos
1 shared publication
Latest Publications
- 1 October 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9700) , 1477-1478
Progress in primary CNS lymphoma
- 1 October 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9700) , 1477-1478
Progress in primary CNS lymphoma
- 1 September 2004
- Published by Wiley in Australasian Radiology
- Vol. 48 (3) , 371-375
All delays before radiotherapy risk progression of Merkel cell carcinoma
Summary: Prolonged waiting times for radiotherapy have resulted in many centres assigning priorities to various patient or diagnostic groups. A high risk of progression on a waiting list is one factor that would reasonably influence the priority. The present descriptive study of 27 patients with Merkel cell carcinoma (MCC) found that a median wait of 24 days for radiotherapy is associated with a high risk of progression. Eleven (41%) of 27 patients developed progressive disease, including five (45%) of 11 patients waiting for adjuvant radiotherapy. Patients treated adjuvantly also had longer waiting times prior to their initial radiotherapy consultation (median 41 days), which may have contributed to the rate of progression. Merkel cell carcinoma is an aggressive but curable malignancy and appropriate management should include efforts to minimize all potential delays prior to the commencement of radiotherapy.
- 1 September 2004
- Published by Wiley in Australasian Radiology
- Vol. 48 (3) , 371-375
All delays before radiotherapy risk progression of Merkel cell carcinoma
Summary: Prolonged waiting times for radiotherapy have resulted in many centres assigning priorities to various patient or diagnostic groups. A high risk of progression on a waiting list is one factor that would reasonably influence the priority. The present descriptive study of 27 patients with Merkel cell carcinoma (MCC) found that a median wait of 24 days for radiotherapy is associated with a high risk of progression. Eleven (41%) of 27 patients developed progressive disease, including five (45%) of 11 patients waiting for adjuvant radiotherapy. Patients treated adjuvantly also had longer waiting times prior to their initial radiotherapy consultation (median 41 days), which may have contributed to the rate of progression. Merkel cell carcinoma is an aggressive but curable malignancy and appropriate management should include efforts to minimize all potential delays prior to the commencement of radiotherapy.
- 1 January 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (1) , 75-80
Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer
- 1 January 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 58 (1) , 75-80
Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer